Free tool
FAERS Monitor: Xatmep
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208400 or its brand name (Xatmep, Methotrexate Sodium). Reports on generic versions are filed under their own applications.
Reports
415,567
Serious
315,085
76% of reports
Hospitalization
119,690
Death reported
34,393
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective75,830
- rheumatoid arthritis38,596
- arthralgia36,779
- pain35,909
- off label use35,261
- fatigue29,599
- nausea24,360
- joint swelling22,621
- headache21,285
- rash20,347
- condition aggravated20,228
- drug intolerance20,017
- diarrhoea18,642
- pain in extremity18,097
- pyrexia17,468
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5,129 |
| 2005 | 5,083 |
| 2006 | 4,969 |
| 2007 | 7,782 |
| 2008 | 8,995 |
| 2009 | 9,160 |
| 2010 | 9,678 |
| 2011 | 10,610 |
| 2012 | 14,953 |
| 2013 | 16,975 |
| 2014 | 16,960 |
| 2015 | 20,301 |
| 2016 | 21,746 |
| 2017 | 22,400 |
| 2018 | 31,889 |
| 2019 | 32,100 |
| 2020 | 39,618 |
| 2021 | 26,418 |
| 2022 | 29,158 |
| 2023 | 26,798 |
| 2024 | 23,076 |
| 2025 | 20,037 |
| 2026 | 11,723 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,638,592 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rheumatoid arthritisSignal | 38,596 | 25.5 | 25.2 | 604,255 |
| drug intoleranceSignal | 20,017 | 13.0 | 12.8 | 176,060 |
| joint swellingSignal | 22,621 | 11.4 | 11.3 | 176,157 |
| arthralgiaSignal | 36,779 | 4.8 | 4.8 | 103,357 |
| condition aggravatedSignal | 20,228 | 3.5 | 3.5 | 34,845 |
| pain in extremitySignal | 18,097 | 3.2 | 3.2 | 26,777 |
| painSignal | 35,909 | 3.1 | 3.0 | 48,927 |
| drug ineffectiveSignal | 75,830 | 3.0 | 3.0 | 103,614 |
| pyrexiaSignal | 17,468 | 2.6 | 2.6 | 17,146 |
| rashSignal | 20,347 | 2.4 | 2.4 | 16,654 |
| off label useSignal | 35,261 | 2.1 | 2.1 | 19,846 |
| fatigue | 29,599 | 2.0 | 1.9 | 13,917 |
| headache | 21,285 | 1.7 | 1.7 | 6,719 |
| nausea | 24,360 | 1.6 | 1.6 | 5,157 |
| diarrhoea | 18,642 | 1.5 | 1.5 | 2,861 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.